Catadegbrutinib (BGB-16673) is a potent, highly selective BTK targeted protein degrader. It affects B-cell receptor (BCR) signaling by inducing the ubiquitination and proteasomal degradation of wild-type and mutant BTK, effectively inhibiting B-cell proliferation and tumor growth in B-cell malignancies.
Catadegbrutinib (BGB-16673) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Catadegbrutinib (BGB-16673) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.